This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Neurology

Depression

Annexin A2 (ANXA2); helicase-like transcription factor (HLTF; SMARCA3); S100 calcium binding protein A10 (S100A10; P11)

Mouse and in vitro studies suggest targeting SMARCA3 signaling could help treat depression. A series of in vitro and mouse studies identified SMARCA3 as a binding partner of the P11-ANXA2 complex, which regulates response to serotonin-specific reuptake inhibitor (SSRI) antidepressants. In Smarca3 knockout mice, Prozac-induced neuronal and behavioral responses were lower than those seen in wild-type controls. Next steps include identifying the genes targeted by the P11-ANXA2 complex in neuronal cells and determining how those genes contribute to the effects of SSRI drugs.
Eli Lilly and Co. markets Prozac fluoxetine to treat major depressive disorder, obsessive-compulsive disorder (OCD), bulimia nervosa and panic disorder.

SciBX 6(9); doi:10.1038/scibx.2013.222
Published online March 7, 2013

Patent and licensing status undisclosed

Oh, Y.-S. et al. Cell; published online Feb. 14, 2013;
doi:10.1016/j.cell.2013.01.014
Contact: Paul Greengard, The Rockefeller University, New York, N.Y.
e-mail:

greengard@rockefeller.edu
Contact: Yong Kim, same affiliation as above
e-mail:

kimyo@rockefeller.edu